Is FOCL or ANGO more profitable?

AngioDynamics has a net margin of -11.48% compared to FocalTherics' net margin of -56.26%. AngioDynamics' return on equity of -5.73% beat FocalTherics' return on equity. Company Net Margins Return on Equity Return on Assets FocalTherics -56.26% -248.00% -44.69% AngioDynamics -11.48% -5.73% -3.77%

Is BWAY or FOCL more profitable?

Brainsway has a net margin of 15.65% compared to FocalTherics' net margin of -56.26%. Brainsway's return on equity of 12.74% beat FocalTherics' return on equity. Company Net Margins Return on Equity Return on Assets Brainsway 15.65% 12.74% 8.17% FocalTherics -56.26% -248.00% -44.69%

FocalTherics (FOCL) Competitors

$4.20 -0.12 (-2.78%)

As of 04:00 PM Eastern

Compare

FOCL vs. ANGO, KIDS, SSII, DCTH, and BWAY

Should you buy FocalTherics stock or one of its competitors? FocalTherics's main competitors and comparable companies include AngioDynamics (ANGO), OrthoPediatrics (KIDS), SS Innovations International (SSII), Delcath Systems (DCTH), and Brainsway (BWAY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does FocalTherics compare to AngioDynamics?

FocalTherics (NASDAQ:FOCL) and AngioDynamics (NASDAQ:ANGO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

AngioDynamics has a net margin of -11.48% compared to FocalTherics' net margin of -56.26%. AngioDynamics' return on equity of -5.73% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FocalTherics	-56.26%	-248.00%	-44.69%
AngioDynamics	-11.48%	-5.73%	-3.77%

FocalTherics has higher earnings, but lower revenue than AngioDynamics. AngioDynamics is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FocalTherics	$70.53M	2.29	-$29.25M	-$1.03	N/A
AngioDynamics	$320.17M	2.01	-$36.74M	-$0.87	N/A

62.7% of FocalTherics shares are owned by institutional investors. Comparatively, 89.4% of AngioDynamics shares are owned by institutional investors. 10.1% of FocalTherics shares are owned by insiders. Comparatively, 6.0% of AngioDynamics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

FocalTherics presently has a consensus price target of $7.75, indicating a potential upside of 80.23%. AngioDynamics has a consensus price target of $19.50, indicating a potential upside of 27.62%. Given FocalTherics' higher probable upside, analysts plainly believe FocalTherics is more favorable than AngioDynamics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FocalTherics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
AngioDynamics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40

In the previous week, AngioDynamics had 3 more articles in the media than FocalTherics. MarketBeat recorded 3 mentions for AngioDynamics and 0 mentions for FocalTherics. AngioDynamics' average media sentiment score of 1.00 beat FocalTherics' score of 0.00 indicating that AngioDynamics is being referred to more favorably in the news media.

Company	Overall Sentiment
FocalTherics	Neutral
AngioDynamics	Positive

FocalTherics has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market. Comparatively, AngioDynamics has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market.

Summary

AngioDynamics beats FocalTherics on 10 of the 15 factors compared between the two stocks.

How does FocalTherics compare to OrthoPediatrics?

OrthoPediatrics (NASDAQ:KIDS) and FocalTherics (NASDAQ:FOCL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

FocalTherics has lower revenue, but higher earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OrthoPediatrics	$236.35M	2.43	-$39.65M	-$1.68	N/A
FocalTherics	$70.53M	2.29	-$29.25M	-$1.03	N/A

OrthoPediatrics presently has a consensus price target of $26.44, suggesting a potential upside of 20.37%. FocalTherics has a consensus price target of $7.75, suggesting a potential upside of 80.23%. Given FocalTherics' higher probable upside, analysts plainly believe FocalTherics is more favorable than OrthoPediatrics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
FocalTherics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

In the previous week, OrthoPediatrics had 3 more articles in the media than FocalTherics. MarketBeat recorded 3 mentions for OrthoPediatrics and 0 mentions for FocalTherics. OrthoPediatrics' average media sentiment score of 0.00 equaled FocalTherics'average media sentiment score.

Company	Overall Sentiment
OrthoPediatrics	Neutral
FocalTherics	Neutral

OrthoPediatrics has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market. Comparatively, FocalTherics has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market.

OrthoPediatrics has a net margin of -15.72% compared to FocalTherics' net margin of -56.26%. OrthoPediatrics' return on equity of -8.10% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OrthoPediatrics	-15.72%	-8.10%	-5.54%
FocalTherics	-56.26%	-248.00%	-44.69%

69.1% of OrthoPediatrics shares are owned by institutional investors. Comparatively, 62.7% of FocalTherics shares are owned by institutional investors. 32.5% of OrthoPediatrics shares are owned by company insiders. Comparatively, 10.1% of FocalTherics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

OrthoPediatrics beats FocalTherics on 11 of the 16 factors compared between the two stocks.

How does FocalTherics compare to SS Innovations International?

FocalTherics (NASDAQ:FOCL) and SS Innovations International (NASDAQ:SSII) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

62.7% of FocalTherics shares are owned by institutional investors. 10.1% of FocalTherics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

FocalTherics presently has a consensus price target of $7.75, indicating a potential upside of 80.23%. SS Innovations International has a consensus price target of $7.00, indicating a potential upside of 156.88%. Given SS Innovations International's higher possible upside, analysts plainly believe SS Innovations International is more favorable than FocalTherics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FocalTherics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, SS Innovations International had 5 more articles in the media than FocalTherics. MarketBeat recorded 5 mentions for SS Innovations International and 0 mentions for FocalTherics. SS Innovations International's average media sentiment score of 0.25 beat FocalTherics' score of 0.00 indicating that SS Innovations International is being referred to more favorably in the news media.

Company	Overall Sentiment
FocalTherics	Neutral
SS Innovations International	Neutral

FocalTherics has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market. Comparatively, SS Innovations International has a beta of -1.79, suggesting that its share price is 279% less volatile than the broader market.

SS Innovations International has lower revenue, but higher earnings than FocalTherics. SS Innovations International is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FocalTherics	$70.53M	2.29	-$29.25M	-$1.03	N/A
SS Innovations International	$42.49M	12.85	-$12.13M	-$0.06	N/A

SS Innovations International has a net margin of -23.73% compared to FocalTherics' net margin of -56.26%. SS Innovations International's return on equity of -26.77% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FocalTherics	-56.26%	-248.00%	-44.69%
SS Innovations International	-23.73%	-26.77%	-15.01%

Summary

SS Innovations International beats FocalTherics on 9 of the 17 factors compared between the two stocks.

How does FocalTherics compare to Delcath Systems?

FocalTherics (NASDAQ:FOCL) and Delcath Systems (NASDAQ:DCTH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

FocalTherics presently has a consensus target price of $7.75, indicating a potential upside of 80.23%. Delcath Systems has a consensus target price of $23.17, indicating a potential upside of 52.10%. Given FocalTherics' higher possible upside, equities research analysts plainly believe FocalTherics is more favorable than Delcath Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FocalTherics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Delcath Systems	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, Delcath Systems had 2 more articles in the media than FocalTherics. MarketBeat recorded 2 mentions for Delcath Systems and 0 mentions for FocalTherics. Delcath Systems' average media sentiment score of 0.76 beat FocalTherics' score of 0.00 indicating that Delcath Systems is being referred to more favorably in the news media.

Company	Overall Sentiment
FocalTherics	Neutral
Delcath Systems	Positive

62.7% of FocalTherics shares are owned by institutional investors. Comparatively, 61.1% of Delcath Systems shares are owned by institutional investors. 10.1% of FocalTherics shares are owned by insiders. Comparatively, 19.4% of Delcath Systems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

FocalTherics has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

Delcath Systems has higher revenue and earnings than FocalTherics. FocalTherics is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FocalTherics	$70.53M	2.29	-$29.25M	-$1.03	N/A
Delcath Systems	$85.23M	6.20	$2.70M	$0.01	1,523.10

Delcath Systems has a net margin of 0.56% compared to FocalTherics' net margin of -56.26%. Delcath Systems' return on equity of 0.46% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FocalTherics	-56.26%	-248.00%	-44.69%
Delcath Systems	0.56%	0.46%	0.42%

Summary

Delcath Systems beats FocalTherics on 14 of the 16 factors compared between the two stocks.

How does FocalTherics compare to Brainsway?

Brainsway (NASDAQ:BWAY) and FocalTherics (NASDAQ:FOCL) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.

30.1% of Brainsway shares are held by institutional investors. Comparatively, 62.7% of FocalTherics shares are held by institutional investors. 19.0% of Brainsway shares are held by insiders. Comparatively, 10.1% of FocalTherics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Brainsway has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market. Comparatively, FocalTherics has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market.

Brainsway presently has a consensus price target of $18.20, indicating a potential upside of 45.19%. FocalTherics has a consensus price target of $7.75, indicating a potential upside of 80.23%. Given FocalTherics' higher probable upside, analysts plainly believe FocalTherics is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainsway	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
FocalTherics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

Brainsway has a net margin of 15.65% compared to FocalTherics' net margin of -56.26%. Brainsway's return on equity of 12.74% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainsway	15.65%	12.74%	8.17%
FocalTherics	-56.26%	-248.00%	-44.69%

Brainsway has higher earnings, but lower revenue than FocalTherics. FocalTherics is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainsway	$52.22M	9.65	$7.57M	$0.44	28.49
FocalTherics	$70.53M	2.29	-$29.25M	-$1.03	N/A

In the previous week, Brainsway had 1 more articles in the media than FocalTherics. MarketBeat recorded 1 mentions for Brainsway and 0 mentions for FocalTherics. FocalTherics' average media sentiment score of 0.00 beat Brainsway's score of -0.21 indicating that FocalTherics is being referred to more favorably in the news media.

Company	Overall Sentiment
Brainsway	Neutral
FocalTherics	Neutral

Summary

Brainsway beats FocalTherics on 12 of the 17 factors compared between the two stocks.

Get FocalTherics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FOCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FOCL vs. The Competition

Export

Metric	FocalTherics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$157.63M	$5.36B	$7.09B	$13.24B
Dividend Yield	N/A	1.80%	2.53%	15.88%
P/E Ratio	-4.08	24.66	274.61	26.05
Price / Sales	2.23	41.73	600.52	89.39
Price / Cash	N/A	32.68	77.38	51.25
Price / Book	8.08	5.68	10.92	6.31
Net Income	-$29.25M	$152.11M	$3.50B	$361.43M
7 Day Performance	-10.83%	-2.01%	-2.11%	-1.67%
1 Month Performance	-0.47%	-5.42%	-6.34%	-3.94%
1 Year Performance	N/A	2.75%	8.81%	2.77%

FocalTherics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FOCL FocalTherics	4.1355 of 5 stars	$4.20 -2.8%	$7.75 +84.5%	N/A	$157.63M	$70.53M	N/A	230	Positive News
ANGO AngioDynamics	3.772 of 5 stars	$15.60 +0.4%	$19.50 +25.0%	+36.6%	$644.75M	$320.17M	N/A	632	News Coverage
KIDS OrthoPediatrics	2.4983 of 5 stars	$22.76 +0.8%	$26.44 +16.2%	+17.8%	$594.26M	$236.35M	N/A	602	Analyst Upgrade
SSII SS Innovations International	1.9612 of 5 stars	$2.89 flat	$7.00 +142.2%	-61.3%	$579.10M	$42.49M	N/A	483
DCTH Delcath Systems	2.8668 of 5 stars	$15.85 +0.3%	$23.17 +46.2%	+43.3%	$550.00M	$85.23M	1,586.59	156

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FOCL) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

FocalTherics (FOCL) Competitors

FOCL vs. ANGO, KIDS, SSII, DCTH, and BWAY

How does FocalTherics compare to AngioDynamics?

Summary

How does FocalTherics compare to OrthoPediatrics?

Summary

How does FocalTherics compare to SS Innovations International?

Summary

How does FocalTherics compare to Delcath Systems?

Summary

How does FocalTherics compare to Brainsway?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FOCL vs. The Competition

FocalTherics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

FocalTherics (FOCL) Competitors

FOCL vs. ANGO, KIDS, SSII, DCTH, and BWAY

How does FocalTherics compare to AngioDynamics?

Is FOCL or ANGO more profitable?

Which has higher valuation & earnings, FOCL or ANGO?

Do insiders and institutionals believe in FOCL or ANGO?

Do analysts recommend FOCL or ANGO?

Does the media prefer FOCL or ANGO?

Which has more volatility and risk, FOCL or ANGO?

Summary

How does FocalTherics compare to OrthoPediatrics?

Which has preferable earnings & valuation, KIDS or FOCL?

Do analysts recommend KIDS or FOCL?

Does the media favor KIDS or FOCL?

Which has more volatility & risk, KIDS or FOCL?

Is KIDS or FOCL more profitable?

Do institutionals and insiders hold more shares of KIDS or FOCL?

Summary

How does FocalTherics compare to SS Innovations International?

Do institutionals and insiders have more ownership in FOCL or SSII?

Do analysts rate FOCL or SSII?

Does the media refer more to FOCL or SSII?

Which has more volatility & risk, FOCL or SSII?

Which has higher earnings and valuation, FOCL or SSII?

Is FOCL or SSII more profitable?

Summary

How does FocalTherics compare to Delcath Systems?

Do analysts recommend FOCL or DCTH?

Does the media refer more to FOCL or DCTH?

Do institutionals and insiders believe in FOCL or DCTH?

Which has more volatility and risk, FOCL or DCTH?

Which has higher earnings & valuation, FOCL or DCTH?

Is FOCL or DCTH more profitable?

Summary

How does FocalTherics compare to Brainsway?

Do institutionals and insiders believe in BWAY or FOCL?

Which has more risk and volatility, BWAY or FOCL?

Do analysts prefer BWAY or FOCL?

Is BWAY or FOCL more profitable?

Which has preferable earnings and valuation, BWAY or FOCL?

Does the media prefer BWAY or FOCL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FOCL vs. The Competition

FocalTherics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools